The University of Wisconsin Carbone Cancer Center (UWCCC) Protocol Review and Monitoring System (PRMS) operates via one main committee, the Protocol Review and Monitoring Committee (PRMC), which functions as the Scientific Review Committee for alt cancer-related research protocols. The PRMC is charged with the scientific and resource review of all new and ongoing clinical and translational research protocols. In addition, the PRMC reviews all cancer-related clinical and translational research for compliance with the UW-Madison Conflict of Interest policies and assures an appropriate Data and Safety and Monitoring Plan is included in each proposal. The PRMC accomplishes this via the following responsibilities; Review of all new clinical and translational trials for scientific merit, priorities and resource allocation Prioritization of new clinical and translational trials relative to the clinical Disease Oriented Working Groups (DOWG)/Clinical Research Groups (CRG) Prioritization of research relative to the scope of UWCCC Review of all ongoing clinical and translational trials for scientific progress Closing studies for insufficient progress or due to prioritization changes Through established procedures the PRMC is the oversight mechanism through which all UW-Madison cancer-related clinical and translational research must flow, thus assuring that all research conducted at UWCCC is of the highest scientific merit and that UWCCC resources are used efficiently. The PRMS is supervised by the Associate Director for Clinical Research. The PRMC reports to UWCCC Clinical Research Committee, and is chaired by Dan Mulkerin, M.D., Associate Professor of Medicine, and co-chaired by Menggang Yu, Ph.D., Assistant Professor of Biostatistics and Medical Informatics. Dr. Mulkerin has over 15 years of clinical research performance and monitoring. Dr. Yu served as the biostatistics and clinical data management director for the Hoosier Oncology Group for four years prior to joining the University of Wisconsin faculty in January 2012.

Public Health Relevance

The UWCCC Protocol Review and Monitoring System (PRMS) operates via one main committee, the Protocol Review and Monitoring Committee (PRMC), which functions as the Scientific Review Committee for all cancer-related research protocols. The PRMC is charged with the scientific and resource review of all new and ongoing clinical and translational research protocols. In addition, the PRMC reviews all cancer related clinical and translational research for compliance with the UW-Madison Conflict of Interest policies and assures an appropriate Data and Safety and Monitoring Plan is included in each proposal.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
4P30CA014520-42
Application #
9067942
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
42
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Wu, Yirong; Fan, Jun; Peissig, Peggy et al. (2018) Quantifying predictive capability of electronic health records for the most harmful breast cancer. Proc SPIE Int Soc Opt Eng 10577:
Fu, Anqi; Oberholtzer, Sydney M; Bagheri-Fam, Stefan et al. (2018) Dynamic expression patterns of Irx3 and Irx5 during germline nest breakdown and primordial follicle formation promote follicle survival in mouse ovaries. PLoS Genet 14:e1007488
Ni, Dalong; Jiang, Dawei; Kutyreff, Christopher J et al. (2018) Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun 9:5421
Huynh, Mailee; Pak, Chorom; Markovina, Stephanie et al. (2018) Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem 293:2452-2465
Farrell, Emily; Armstrong, Annie E; Grimes, Adrian C et al. (2018) Transcriptome Analysis of Cardiac Hypertrophic Growth in MYBPC3-Null Mice Suggests Early Responders in Hypertrophic Remodeling. Front Physiol 9:1442
Net, Jose M; Whitman, Gary J; Morris, Elizabteh et al. (2018) Relationships Between Human-Extracted MRI Tumor Phenotypes of Breast Cancer and Clinical Prognostic Indicators Including Receptor Status and Molecular Subtype. Curr Probl Diagn Radiol :
Jiang, Dawei; Ge, Zhilei; Im, Hyung-Jun et al. (2018) DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng 2:865-877
Seok, Seung-Hyeon; Ma, Zhi-Xiong; Feltenberger, John B et al. (2018) Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J Biol Chem 293:1994-2005
Chapelin, Fanny; Capitini, Christian M; Ahrens, Eric T (2018) Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer. J Immunother Cancer 6:105
Ni, Dalong; Ferreira, Carolina A; Barnhart, Todd E et al. (2018) Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. J Am Chem Soc 140:14971-14979

Showing the most recent 10 out of 1528 publications